86 related articles for article (PubMed ID: 26659584)
1. Early metabolic change in (18)F-FDG-PET by measuring the single largest lesion predicts chemotherapeutic effects and patients' survival: PEACH study.
Tanaka Y; Ueda Y; Egawa-Takata T; Matsuzaki S; Kobayashi E; Yoshino K; Enomoto T; Tatsumi M; Kimura T
Cancer Chemother Pharmacol; 2016 Jan; 77(1):121-6. PubMed ID: 26659584
[TBL] [Abstract][Full Text] [Related]
2. Is ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?
Yang JJ; Wang SX; Zhong WZ; Xu CR; Yan HH; Wu YL
Nucl Med Commun; 2011 Dec; 32(12):1113-20. PubMed ID: 21934546
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma.
Zhao J; Qiao W; Wang C; Wang T; Xing Y
Hematology; 2007 Oct; 12(5):423-30. PubMed ID: 17852456
[TBL] [Abstract][Full Text] [Related]
4. ¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.
Groheux D; Biard L; Giacchetti S; Teixeira L; Hindié E; Cuvier C; Vercellino L; Merlet P; de Roquancourt A; de Cremoux P; Resche-Rigon M; Espié M
J Nucl Med; 2016 Apr; 57(4):536-43. PubMed ID: 26697967
[TBL] [Abstract][Full Text] [Related]
5. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
Schaefer NG; Veit-Haibach P; Soyka JD; Steinert HC; Stahel RA
Eur J Radiol; 2012 Jan; 81(1):e19-25. PubMed ID: 21129871
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive role of [
Zucali PA; Lopci E; Ceresoli GL; Giordano L; Perrino M; Ciocia G; Gianoncelli L; Lorenzi E; Simonelli M; De Vincenzo F; Setti LR; Bonifacio C; Bonomi M; Bombardieri E; Chiti A; Santoro A
Cancer Med; 2017 Oct; 6(10):2287-2296. PubMed ID: 28941158
[TBL] [Abstract][Full Text] [Related]
7. Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.
Lastoria S; Piccirillo MC; Caracò C; Nasti G; Aloj L; Arrichiello C; de Lutio di Castelguidone E; Tatangelo F; Ottaiano A; Iaffaioli RV; Izzo F; Romano G; Giordano P; Signoriello S; Gallo C; Perrone F
J Nucl Med; 2013 Dec; 54(12):2062-9. PubMed ID: 24136935
[TBL] [Abstract][Full Text] [Related]
8. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Haematologica; 2000 Jun; 85(6):613-8. PubMed ID: 10870118
[TBL] [Abstract][Full Text] [Related]
9. Metabolic response to preoperative chemotherapy predicts prognosis for patients undergoing surgical resection of colorectal cancer metastatic to the liver.
Lau LF; Williams DS; Lee ST; Scott AM; Christophi C; Muralidharan V
Ann Surg Oncol; 2014 Jul; 21(7):2420-8. PubMed ID: 24595797
[TBL] [Abstract][Full Text] [Related]
10. Predicting outcome in patients with rhabdomyosarcoma: role of [(18)f]fluorodeoxyglucose positron emission tomography.
Casey DL; Wexler LH; Fox JJ; Dharmarajan KV; Schoder H; Price AN; Wolden SL
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1136-42. PubMed ID: 25539372
[TBL] [Abstract][Full Text] [Related]
11. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
Kostakoglu L; Coleman M; Leonard JP; Kuji I; Zoe H; Goldsmith SJ
J Nucl Med; 2002 Aug; 43(8):1018-27. PubMed ID: 12163626
[TBL] [Abstract][Full Text] [Related]
12. Fluorine 18 fluorodeoxyglucose PET/CT volume-based indices in locally advanced non-small cell lung cancer: prediction of residual viable tumor after induction chemotherapy.
Soussan M; Cyrta J; Pouliquen C; Chouahnia K; Orlhac F; Martinod E; Eder V; Morère JF; Buvat I
Radiology; 2014 Sep; 272(3):875-84. PubMed ID: 24761836
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study.
Sachpekidis C; Larribere L; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A; Hassel JC
Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):386-96. PubMed ID: 25359635
[TBL] [Abstract][Full Text] [Related]
14. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors.
Hawkins DS; Schuetze SM; Butrynski JE; Rajendran JG; Vernon CB; Conrad EU; Eary JF
J Clin Oncol; 2005 Dec; 23(34):8828-34. PubMed ID: 16314643
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
Gebhart G; Gámez C; Holmes E; Robles J; Garcia C; Cortés M; de Azambuja E; Fauria K; Van Dooren V; Aktan G; Coccia-Portugal MA; Kim SB; Vuylsteke P; Cure H; Eidtmann H; Baselga J; Piccart M; Flamen P; Di Cosimo S
J Nucl Med; 2013 Nov; 54(11):1862-8. PubMed ID: 24092940
[TBL] [Abstract][Full Text] [Related]
16. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
[TBL] [Abstract][Full Text] [Related]
17. FDG-PET as a potential tool for selecting patients with advanced non-small cell lung cancer who may be spared maintenance therapy after first-line chemotherapy.
Yoon DH; Baek S; Choi CM; Lee DH; Suh C; Ryu JS; Moon DH; Lee JS; Kim SW
Clin Cancer Res; 2011 Aug; 17(15):5093-100. PubMed ID: 21673067
[TBL] [Abstract][Full Text] [Related]
18. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.
Francis RJ; Byrne MJ; van der Schaaf AA; Boucek JA; Nowak AK; Phillips M; Price R; Patrikeos AP; Musk AW; Millward MJ
J Nucl Med; 2007 Sep; 48(9):1449-58. PubMed ID: 17704250
[TBL] [Abstract][Full Text] [Related]
19. Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma.
Lopci E; Zucali PA; Ceresoli GL; Perrino M; Giordano L; Gianoncelli L; Lorenzi E; Gemelli M; Santoro A; Chiti A
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):667-75. PubMed ID: 25403555
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
